Solventum

Solventum shares rose to a new 52-week high of $88.21, gaining nearly 11% on the week. The health‑technology company has a market capitalization of $14.92 billion and is up about 20.6% year to date. Solventum beat expectations in Q1 of fiscal 2026 with EPS of $1.48 (forecast $1.34) on organic revenue growth of 2.1%. Analysts rated the stock positively; the P/E ratio is around 9.3, which the fair‑value estimate signals as a slight overvaluation. » More on de.investing.com

UBS upgraded Solventum from “Neutral” to “Buy” and set a $95 price target, implying roughly 18% upside. The stock rose 7.6% in morning trading and hit a daily high of $87.19, close to its 52-week high of $88.20. Earlier positive analyst notes from BTIG and KeyBanc, along with four consecutive quarters of EPS beats, underpin expectations for a strong Q2 report on Aug. 5. The rally was stock-specific while broad US indices were mostly weaker. » More on de.investing.com

Trian Fund Management has disclosed just under a 5% stake in Solventum and, in an open letter, demanded three value-boosting measures: reduce overhead to 3M-levels, sell non-core divisions including Health Information Systems, and prioritize share buybacks. Trian criticizes that the market capitalization of around $12 billion is far below the $25 billion expected at the spin-off and sees about $13 billion of shareholder value destroyed. The investor also condemns high executive compensation since the spin-off without corresponding returns for shareholders and says it will communicate with other large shareholders and may adjust its position. » More on de.investing.com